α發射體(α發射體)市場:各放射性核種類型，各醫療用途，各地區 - 市場規模，佔有率，展望，機會分析，2023年～2030年

Alpha Emitter Market, By Type of Radionuclide (Radium, Actinium, and Lead ), By Medical Applications, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年06月19日 | 出版商:

Coherent Market Insights | 英文 171 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

市場動態:

癌症負擔的增加、老年人口的增加、癌症治療中靶向α療法（TAT）的使用增加、對TAT潛在益處的認識的提高以及研究和開發的增加預計將推動全球癌症治療的增長阿爾法發射器市場。

本調查的主要特徵

本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球α發射體(α發射體)市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球α發射體(α發射體)市場的主要參與者之企業簡介。
藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
全球α發射體(α發射體)市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以透過全球α發射體(α發射體)市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

Alpha emitters play a significant role in the treatment of different types of cancer. Targeted alpha therapy (TAT) is a therapeutic option in patients with multiple micro-metastases. Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancer. Properties of alpha emitters have led to exert profound differences between this field and other fields of nuclear medicine.

Market Dynamics:

Increase in burden of cancer, rise in geriatric population, increase in use of targeted alpha therapy (TAT) for cancer treatment, rise in awareness about the potential benefits of TAT, and increase in research and development are expected to propel the growth of the global alpha emitter market.

For instance, in July 2021, Alpha Tau Medical Ltd. and Healthcare Capital Corporation signed an agreement to further expand Alpha Tau's clinical strategy, including the pursuit of FDA (Food and Drug Administration) marketing authorization, a broad array of R&D (research and development) activities, expanding manufacturing capacity, and preparing for commercialization.

Key features of the study:

This report provides in-depth analysis of the global alpha emitter market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global alpha emitter market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Bayer AG, Alpha Tau Medical Ltd., Fusion Pharmaceuticals, Telix Pharmaceuticals, Orano Group (Orano Med), NOVARTIS AG (Endocyte Inc.), and Actinium Pharmaceutical Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global alpha emitter market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global alpha emitter market.

Detailed Segmentation:

Global Alpha Emitter Market, By Type of Radionuclide:
- Radium (Ra-223)
- Actinium (Ac-225)
- Lead (Pb-212)
Global Alpha Emitter Market, By Medical Applications:
- Prostate Cancer
- Bone Metastases
- Ovarian Cancer
- Pancreatic Cancer
- Endocrine Tumors
- Other Medical Applications
Global Alpha Emitter Market, By Geography:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Company Profiles:
- Bayer AG
- Alpha Tau Medical Ltd.
- Fusion Pharmaceuticals
- Telix Pharmaceuticals Ltd.
- Orano Group (Orano Med)
- NOVARTIS AG (Endocyte Inc.)
- Actinium Pharmaceutical Inc.

Market Dynamics
- Rise in burden of cancer and rise in geriatric population
- Stringent regulations and need for high capital investment
- Increase in adoption/use of targeted alpha therapy (TAT)
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Alpha Emitter Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Alpha Emitter Market, By Type of Radionuclide, 2023-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Radium (Ra-223)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Actinium (Ac-225)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Lead (Pb-212)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Alpha Emitter Market, By Medical Applications, 2023-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Bone Metastases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Pancreatic Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Endocrine Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Other Medical Applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Alpha Emitter Market, By Geography, 2023-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Medical Applications, 2017-2030,(US$ Mn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Medical Applications, 2017-2030,(US$ Mn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Medical Applications, 2017-2030,(US$ Mn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Medical Applications, 2017-2030,(US$ Mn)
Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Medical Applications, 2017-2030,(US$ Mn)

8. Competitive Landscape

Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Alpha Tau Medical Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Fusion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Telix Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Orano Group (Orano Med)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
NOVARTIS AG (Endocyte Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Actinium Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views